234 related articles for article (PubMed ID: 29045509)
21. Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development.
Hammood M; Craig AW; Leyton JV
Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358100
[TBL] [Abstract][Full Text] [Related]
22. Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases.
Yap ML; McFadyen JD; Wang X; Ziegler M; Chen YC; Willcox A; Nowell CJ; Scott AM; Sloan EK; Hogarth PM; Pietersz GA; Peter K
Theranostics; 2019; 9(4):1154-1169. PubMed ID: 30867822
[No Abstract] [Full Text] [Related]
23. Computational Approaches in Antibody-drug Conjugate Optimization for Targeted Cancer Therapy.
Melo R; Lemos A; Preto AJ; Almeida JG; Correia JDG; Sensoy O; Moreira IS
Curr Top Med Chem; 2018; 18(13):1091-1109. PubMed ID: 30068276
[TBL] [Abstract][Full Text] [Related]
24. Antibody-Drug Conjugates: A Review on the Epitome of Targeted Anti- Cancer Therapy.
Hasan M; Alam S; Poddar SK
Curr Clin Pharmacol; 2018; 13(4):236-251. PubMed ID: 30073930
[TBL] [Abstract][Full Text] [Related]
25. Elucidating Novel Targets for Ovarian Cancer Antibody-Drug Conjugate Development: Integrating In Silico Prediction and Surface Plasmon Resonance to Identify Targets with Enhanced Antibody Internalization Capacity.
Onyido EK; James D; Garcia-Parra J; Sinfield J; Moberg A; Coombes Z; Worthington J; Williams N; Francis LW; Conlan RS; Gonzalez D
Antibodies (Basel); 2023 Oct; 12(4):. PubMed ID: 37873862
[TBL] [Abstract][Full Text] [Related]
26. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design.
Trail PA; Dubowchik GM; Lowinger TB
Pharmacol Ther; 2018 Jan; 181():126-142. PubMed ID: 28757155
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells.
Sharma S; Li Z; Bussing D; Shah DK
Drug Metab Dispos; 2020 May; 48(5):368-377. PubMed ID: 32086295
[TBL] [Abstract][Full Text] [Related]
28. Antibody-Drug Conjugates for Breast Cancer.
Marmé F
Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
[TBL] [Abstract][Full Text] [Related]
29. Antibody-drug conjugates as targeted cancer therapeutics.
Sun Y; Yu F; Sun BW
Yao Xue Xue Bao; 2009 Sep; 44(9):943-52. PubMed ID: 20055167
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
[TBL] [Abstract][Full Text] [Related]
31. Advances in anticancer antibody-drug conjugates and immunotoxins.
Dosio F; Stella B; Cerioni S; Gastaldi D; Arpicco S
Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):35-65. PubMed ID: 23477784
[TBL] [Abstract][Full Text] [Related]
32. Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo.
Ma Z; He H; Sun F; Xu Y; Huang X; Ma Y; Zhao H; Wang Y; Wang M; Zhang J
J Cancer Res Clin Oncol; 2017 Oct; 143(10):1929-1940. PubMed ID: 28536738
[TBL] [Abstract][Full Text] [Related]
33. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.
M-Rabet M; Cabaud O; Josselin E; Finetti P; Castellano R; Farina A; Agavnian-Couquiaud E; Saviane G; Collette Y; Viens P; Gonçalves A; Ginestier C; Charafe-Jauffret E; Birnbaum D; Olive D; Bertucci F; Lopez M
Ann Oncol; 2017 Apr; 28(4):769-776. PubMed ID: 27998973
[TBL] [Abstract][Full Text] [Related]
34. Antibody-drug conjugates in cancer therapy.
Sievers EL; Senter PD
Annu Rev Med; 2013; 64():15-29. PubMed ID: 23043493
[TBL] [Abstract][Full Text] [Related]
35. Computational selection of antibody-drug conjugate targets for breast cancer.
Fauteux F; Hill JJ; Jaramillo ML; Pan Y; Phan S; Famili F; O'Connor-McCourt M
Oncotarget; 2016 Jan; 7(3):2555-71. PubMed ID: 26700623
[TBL] [Abstract][Full Text] [Related]
36. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.
Kamath AV; Iyer S
Pharm Res; 2015 Nov; 32(11):3470-9. PubMed ID: 25446773
[TBL] [Abstract][Full Text] [Related]
37. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
Vezina HE; Cotreau M; Han TH; Gupta M
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
[TBL] [Abstract][Full Text] [Related]
38. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
[TBL] [Abstract][Full Text] [Related]
39. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
40. AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma.
Doñate F; Raitano A; Morrison K; An Z; Capo L; Aviña H; Karki S; Morrison K; Yang P; Ou J; Moriya R; Shostak Y; Malik F; Nadell R; Liu W; Satpayev D; Atkinson J; Joseph IB; Pereira DS; Challita-Eid PM; Stover DR
Clin Cancer Res; 2016 Apr; 22(8):1989-99. PubMed ID: 26589436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
